Sol-Gel Technologies Ltd. (SLGL) Form 6-K — Sep 17, 2026
Sol-Gel Technologies (NASDAQ: SLGL) announced that the last patient has completed the last scheduled study visit (LPLV) in its pivotal Phase 3 trial (SGT-610-01) of SGT-610 (patidegib gel, 2%) for the prevention of new basal cell carcinoma lesions in adults with Gorlin syndrome. The randomized, double-blind, vehicle-controlled study enrolled 113 patients, of whom 102 completed 12 months of twice-daily treatment. The primary endpoint is the number of new facial BCCs at month 12, with new surgically eligible BCCs (SEBCCs) as a secondary endpoint. The company is now proceeding to database lock and statistical analysis, with top-line results on track for late November 2026.
Key figures
- Dosing Frequency
- twice daily
- Primary Endpoint
- number of new BCCs on the face at month 12
- Study Identifier
- SGT-610-01
- Patients Enrolled
- 113
- Patients Completed
- 102
- Secondary Endpoint
- number of new surgically eligible BCCs (SEBCCs)
- Topline Results Timing
- late November 2026
- Treatment Duration Months
- 12
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.